en.Wedoany.com Reported - On June 15, Harbour BioMed and BioMap jointly announced a multi-level, long-term comprehensive strategic partnership, and the establishment of a new global-market-focused AI pipeline R&D company, MegaStream TechBio. The new company will focus on AI-driven R&D for complex macromolecular drugs, with its initial pipeline comprising both previously collaborated AI drug discovery projects and newly initiated AI-native pipeline projects. The founding parties will be entitled to potential upfront payments, success milestones, and royalty sharing in accordance with industry practices.
The core of MegaStream's establishment lies in integrating antibody drug discovery platforms with life science large model capabilities. Harbour BioMed will provide MegaStream with access to its fully human antibody platform, target biology expertise, and global clinical development advantages; BioMap will supply MegaStream with underlying AI technology, model engineering support, and intelligent R&D capabilities. For AI-driven drug development, algorithms are only one component; factors truly impacting pipeline quality include high-quality biological data, experimental validation systems, drug developability assessment, and clinical translation experience. This collaboration aims to integrate these elements into a company platform dedicated to pipeline R&D.
Developing complex macromolecular drugs is highly challenging, involving multiple stages such as sequence design, structural prediction, affinity, stability, immunogenicity, druggability, manufacturing processes, and clinical indication selection. Traditional R&D processes typically require repeated screening, experimental validation, and structural optimization, leading to long timelines and high costs, with early candidate molecules still facing significant uncertainty upon entering clinical trials. MegaStream plans to leverage AI model prediction, high-throughput validation, and a closed-loop dry-wet experimental platform to enhance the efficiency of candidate molecule discovery and optimization, focusing on areas with unmet clinical needs, including cardiovascular, renal, oncology, and anti-aging diseases.
From a technical perspective, MegaStream is not merely building an AI tool software but aims to construct an R&D system that integrates "data, models, experiments, and pipelines." Public information indicates that the two parties will develop a proprietary large model for complex macromolecular drugs, based on BioMap's life science foundational large model platform, xTrimo, and high-quality data accumulated from Harbour BioMed's Harbour Mice® fully human antibody platform. This model will be optimized for directions such as multispecific antibodies, XDC conjugated drugs, in vivo CAR-T, and inhaled or oral macromolecular drugs, serving the R&D process from sequence generation to developability optimization.
The closed-loop dry-wet laboratory is another key component of this collaboration. AI-driven drug discovery, if confined to the computational side, can hardly truly alter R&D outcomes; models require continuous validation through wet experiments, with experimental data fed back into the model for iterative improvement. MegaStream plans to build an intelligent high-throughput closed-loop dry-wet laboratory, covering experimental scheduling, data collection, automated analysis, model training, and result feedback. According to public information, upon completion, this laboratory is expected to improve efficiency by over 500% compared to the previous generation platform, increase data accumulation efficiency by more than tenfold, and generate over 5PB of high-quality AI-Ready life science data within the next five years. These metrics still require validation after the platform's actual operation, but the direction indicates that competition in AI-driven drug development is shifting towards sustainable data and experimental closed-loop capabilities.
For Harbour BioMed, MegaStream allows its antibody platform and clinical development capabilities to further extend into an AI-native pipeline company. The company already possesses antibody technology platforms, R&D expertise in areas like immunology and oncology, and global clinical development experience; by leveraging the new company to undertake AI-driven projects, it can expand its complex macromolecular pipeline layout without fully relying on its internal traditional R&D system. For BioMap, MegaStream provides a vehicle for its life science foundational large model to enter real drug discovery scenarios, enabling a more direct connection between model capabilities and targets, molecular design, experimental validation, and clinical value.
From an industry perspective, AI-driven drug development is transitioning from early-stage "model demonstrations" to "pipeline delivery." In recent years, many AI drug discovery companies have emphasized discovery speed and computational power, but the market ultimately focuses on whether candidate molecules can enter clinical trials, whether clinical data holds up, and how commercial rights are allocated. The initial pipeline of MegaStream comes from previous collaborative projects and newly initiated AI-native projects, indicating that the parties are not starting from scratch but aim to use existing collaboration foundations as launch assets. Whether subsequent clinical-stage candidate drugs can be generated will determine the actual industrial value of this AI pipeline R&D company.
This collaboration is still in the company formation and pipeline initiation phase, with no specific details disclosed regarding financing scale, registered capital, number of initial pipeline projects, or clinical timelines for each project. AI models, fully human antibody platforms, and closed-loop dry-wet laboratories can enhance early-stage R&D efficiency, but drug development still requires stages such as preclinical research, IND filing, clinical trials, and safety and efficacy validation. The subsequent progress of MegaStream will depend on the onboarding of core teams, construction of experimental platforms, quality of pipeline screening, introduction of external partners, and speed of clinical translation.
The joint establishment of MegaStream TechBio by Harbour BioMed and BioMap signifies a deeper integration between Chinese AI drug development companies and biopharmaceutical platform companies. AI is no longer just a point tool in drug discovery but is beginning to form a new R&D company model together with antibody platforms, experimental systems, clinical development, and royalty sharing mechanisms. As complex macromolecular drug development enters a phase of higher costs and intensified competition, the combination of data quality, model capabilities, experimental validation, and clinical execution will be key to whether AI pipeline companies can succeed in the global market.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
